Search Results (6)

Background: Hemodynamic management in veno-arterial extracorporeal membrane oxygenation (V-A ECMO) is inherently complex, as extracorporeal circulation profoundly alters preload, afterload, ventriculo-arterial coupling and tissue perfusion. This review summarizes current and emerging monitoring strategies to guide initiation, maintenance and weaning. Methods: A structured literature search was performed in PubMed and Scopus (1990–2025), including clinical studies, consensus statement and expert reviews addressing hemodynamic monitoring in V-A ECMO. Results: A multiparametric framework is required. Echocardiography remains central for assessing biventricular performance, aortic valve dynamics and ventricular unloading. Pulmonary artery catheterization provides complementary data on filling pressures, cardiac output and global oxygen balance. Metabolic indices such as lactate clearance and veno-arterial CO₂ gap, together with regional oximetry (NIRS), inform the adequacy of systemic and tissue perfusion. Microcirculatory monitoring, though technically demanding, has shown prognostic value, particularly during weaning. Additional adjuncts include arterial pulse pressure, end-tidal CO₂ and waveform analysis. Phenotype oriented priorities, such as detection of differential hypoxemia, prevention of left ventricular distension or surveillance for limb ischemia, require tailored monitoring strategies. Artificial intelligence and machine learning represent future avenues for integrating multiparametric data into predictive models. Conclusions: No single modality can capture the hemodynamic complexity of V-A ECMO. Precision monitoring demands a dynamic, phenotype-specific and time-dependent approach that integrates systemic, cardiac, metabolic and microcirculatory variables. Such individualized strategies hold promise to optimize outcomes, reduce complications and align V-A ECMO management with the principles of precision medicine. Full article

Cardiogenic shock (CS) is a complex, life-threatening syndrome characterized by inadequate tissue perfusion due to impaired cardiac function. Acute myocardial infarction (AMI) and acute decompensated heart failure are the leading causes, with mortality remaining high despite advances in revascularization and supportive care. The Society for Cardiovascular Angiography and Interventions (SCAI) classification allows risk stratification and guides clinical decision making by capturing the spectrum of shock severity. Percutaneous mechanical circulatory support (pMCS) devices, such as the intra-aortic balloon pump (IABP) and Impella, aim to stabilize hemodynamics by augmenting cardiac output and unloading the left ventricle. However, randomized trials and meta-analyses have not demonstrated a consistent survival advantage of Impella over IABP, while reporting higher rates of bleeding and vascular complications. Landmark trials, including ECLS-SHOCK and DanGer, have provided conflicting results, likely reflecting differences in baseline severity and timing of device implantation. Veno-arterial extracorporeal membrane oxygenator (VA-ECMO) offers full cardiopulmonary support but increases left ventricular afterload, potentially worsening myocardial injury. Combined strategies such as ECPELLA (Impella + VA-ECMO) or ECMO + IABP may mitigate left ventricle (LV) overload and improve bridging to recovery or advanced therapies, although evidence remains largely observational and complication rates are considerable. In right-sided or biventricular failure, tailored options (e.g., Impella RP, Bi-Pella) guided by invasive hemodynamics may be required. Current evidence suggests that pMCS benefits are limited to carefully selected subgroups, underscoring the importance of early diagnosis, prompt referral, and individualized intervention. Robust randomized data are still needed to define the optimal role of pMCS in AMI-related CS. Full article

Background and Objectives: Left ventricle (LV) overloading during veno-arterial (VA) extracorporeal membrane oxygenation (ECMO) is detrimental to myocardial recovery. To determine whether LV unloading using transaortic catheter venting (TACV) is effective, we analyzed the effect of TACV in a human-sized porcine model. Materials and Methods: Hypoxic biventricular dysfunction was induced in 11 pigs using femoro-femoral VA-ECMO and custom-made TACV catheters in the LV through the common carotid artery. Hemodynamic conditions were then simulated. The TACV was either opened or closed under a controlled ECMO flow. Conversely, the ECMO flow was adjusted, varying from 1 L to 4 L, with and without TACV; 2115 observations were collected. Results: In comparing observations without TACV (TACV−) and with TACV (TACV+), the change in left ventricular end-diastolic pressure (LVEDP) after TACV application was −1.2 mmHg (p < 0.001). In the linear regression model, the reduction in LVEDP was maximized when the baseline LVEDP and ECMO flow were higher. When escalating the ECMO flow in the respective settings of TACV− and TACV+, the rise in LVEDP was significantly lower in TACV+. Conclusions: TACV decreased LVEDP; this effect was more prominent when ECMO flow and baseline LVEDP were higher. These findings suggest that TACV might support LV recovery through effective unloading, even when ECMO flow is high. Full article

Background: When heart transplantation and myocardial recovery are unlikely, patients presenting with biventricular cardiogenic shock initially treated with extracorporeal membrane oxygenation (ECMO) may benefit from a mechanical support upgrade. In this scenario, a micro-invasive approach is proposed: the combination of the double-lumen ProtekDuo cannula (Livanova, London, UK) and the Impella 5.5 (Abiomed, Danvers, MA) trans-aortic pump that translates into a hybrid BiVAD. Methods: All consecutive ECMO patients presenting with biventricular cardiogenic shock and ineligibility to heart transplantation from August 2022 were prospectively enrolled. The clinical course, procedural details, and in-hospital events were collected via electronic medical records. Results: A total of three patients, who were temporarily not eligible for heart transplantation or durable LVAD due to severe acute pneumonia and right ventricular (RV) dysfunction, were implanted with a hybrid BiVAD. This strategy provided high-flow biventricular support while pulmonary function ameliorated. Moreover, by differentially sustaining the systemic and pulmonary circulation, it allowed for a more adequate reassessment of RV function. All the patients were considered eligible for isolated durable LVAD and underwent less invasive LVAD implantation paired with a planned postoperative RVAD. In all cases, RV function gradually recovered and the RVAD was successfully removed. Conclusions: The Hybrid BiVAD represents an up-to-date micro-invasive mechanical treatment of acute biventricular failure beyond ECMO. Its rationale relies on more physiological circulation across the lungs, the complete biventricular unloading, and the possibility of including an oxygenator in the circuit. Finally, the independent and differential control of pulmonary and systemic flows allows for more accurate RV function evaluation for isolated durable LVAD eligibility reassessment. Full article

Since mechanical circulatory support (MCS) devices have become integral component in the therapy of refractory cardiogenic shock (RCS), we identified 67 patients in biventricular support with Impella and venoarterial Extracorporeal Membrane Oxygenation (VA-ECMO) for RCS between February 2013 and December 2019 and evaluated the risk factors of mortality in this setting. Mean age was 61.07 ± 10.7 and 54 (80.6%) patients were male. Main cause of RCS was acute myocardial infarction (AMI) (74.6%), while 44 (65.7%) were resuscitated prior to admission. The mean Simplified Acute Physiology Score II (SAPS II) and Sequential Organ Failure Assessment Score (SOFA) score on admission was 73.54 ± 16.03 and 12.25 ± 2.71, respectively, corresponding to an expected mortality of higher than 80%. Vasopressor doses and lactate levels were significantly decreased within 72 h on biventricular support (p < 0.05 for both). Overall, 17 (25.4%) patients were discharged to cardiac rehabilitation and 5 patients (7.5%) were bridged successfully to ventricular assist device implantation, leading to a total of 32.8% survival on hospital discharge. The 6-month survival was 31.3%. Lactate > 6 mmol/L, vasoactive score > 100 and pH < 7.26 on initiation of biventricular support, as well as Charlson comorbity index > 3 and prior resuscitation were independent predictors of survival. In conclusion, biventricular support with Impella and VA-ECMO in patients with RCS is feasible and efficient leading to a better survival than predicted through traditional risk scores, mainly via significant hemodynamic improvement and reduction in lactate levels. Full article

Background: Echocardiography-based programming of conduction delays in cardiac resynchronisation therapy is complex and time-consuming. Impedance cardiography (ICG) may be an alternative method. However, it is unknown whether ICG is sensitive enough to detect haemodynamic changes due to different pacing-induced ventricular activation modes. The aim of this study was to determine the ability of ICG to measure haemodynamic changes during different ventricular pacing modes in patients with a cardiac resynchronisation therapy (CRT). Methods: 18 patients were evaluated. Stroke volume (SV), cardiac output (CO) and total peripheral resistance (TPR) were measured by means of ICG. Continuous blood pressure (cBP) was recorded with the vascular unloading technique. Haemodynamic measurements of 10-minute-sampling periods, taken in the supine position, were compared during biventricular (BIV), right (RV) and left ventricular (LV) pacing and intrinsic rhythm (IR). Results: One patient was excluded from the analysis (serious haemodynamic deterioration during IR). The age of the study population was 67 ± 10 years (94% male) with a LV ejection fraction of 26 ± 6%. The majority had left-bundle-branch block (82%). Compared to IR, BIV increased SV (58 ± 11 vs 67 ± 12 ml; p = 0.0007), CO (3.6 ± 0.7 vs 4.2 ± 0.8 l/min; p = 0.0007) and reduced TPR (1975 ± 410 vs 1694 ± 390 dyn*s/cm5). cBP remained unchanged during different ventricular pacing modes. Conclusion: ICG is able to detect intraindividual changes of haemodynamic parameters induced by different pacing modes. However, its sensitivity to detect haemodynamic changes through conduction delay variations, as performed for device optimisation, remains unclear. Full article